Immune Aging in Multiple Sclerosis is Characterized by Abnormal CD4 T Cell Activation and Increased Frequencies of Cytotoxic CD4 T Cells with Advancing Age
Overview
Authors
Affiliations
Background: Immunosenescence (ISC) describes age-related changes in immune-system composition and function. Multiple sclerosis (MS) is a lifelong inflammatory condition involving effector and regulatory T-cell imbalance, yet little is known about T-cell ISC in MS. We examined age-associated changes in circulating T cells in MS compared to normal controls (NC).
Methods: Forty untreated MS (Mean Age 43·3, Range 18-72) and 49 NC (Mean Age 48·6, Range 20-84) without inflammatory conditions were included in cross-sectional design. T-cell subsets were phenotypically and functionally characterized using validated multiparametric flow cytometry. Their aging trajectories, and differences between MS and NC, were determined using linear mixed-effects models.
Findings: MS patients demonstrated early and persistent redistribution of naïve and memory CD4 T-cell compartments. While most CD4 and CD8 T-cell aging trajectories were similar between groups, MS patients exhibited abnormal age-associated increases of activated (HLA-DRCD38; (P = 0·013) and cytotoxic CD4 T cells, particularly in patients >60 (EOMES: P < 0·001). Aging MS patients also failed to upregulate CTLA-4 expression on both CD4 (P = 0·014) and CD8 (P = 0·009) T cells, coupled with abnormal age-associated increases in frequencies of B cells expressing costimulatory molecules.
Interpretation: While many aspects of T-cell aging in MS are conserved, the older MS patients harbour abnormally increased frequencies of CD4 T cells with activated and cytotoxic effector profiles. Age-related decreased expression of T-cell co-inhibitory receptor CTLA-4, and increased B-cell costimulatory molecule expression, may provide a mechanism that drives aberrant activation of effector CD4 T cells that have been implicated in progressive disease.
Funding: Stated in Acknowledgements section of manuscript.
Hecker M, Fitzner B, Ludwig-Portugall I, Bohne F, Heyland E, Klehmet J Front Immunol. 2025; 16:1531447.
PMID: 39949773 PMC: 11821495. DOI: 10.3389/fimmu.2025.1531447.
Desu H, Balthazard R, Daigneault A, Da Cal S, Klement W, Yu J EBioMedicine. 2025; 112:105559.
PMID: 39837012 PMC: 11788784. DOI: 10.1016/j.ebiom.2025.105559.
Bolton C Immun Ageing. 2024; 21(1):73.
PMID: 39438909 PMC: 11494837. DOI: 10.1186/s12979-024-00473-w.
De Biasi S, Ciobanu A, Santacroce E, Lo Tartaro D, Degliesposti G, DAngerio M Vaccines (Basel). 2024; 12(8).
PMID: 39204047 PMC: 11360119. DOI: 10.3390/vaccines12080924.
Neatu M, Hera-Dragut A, Ionita I, Jugurt A, Davidescu E, Popescu B Biomedicines. 2024; 12(8).
PMID: 39200354 PMC: 11351992. DOI: 10.3390/biomedicines12081890.